Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study

ConclusionsThe proportion of patients with an infusion reaction was significantly lower with golimumab-IV vs. infliximab. Among biologic-na ïve patients, mean change from baseline in CDAI at months 6 and 12 was non-inferior for golimumab-IV vs. infliximab. Compared with fixed-dose golimumab-IV, infliximab dose escalation did not provide any greater improvements in CDAI for patients with RA.Trial RegistrationClinicalTrials.gov identifier, NCT02728934.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research